Continuous Glucose Monitoring Profiles and Health Outcomes after Dapagliflozin Plus Saxagliptin vs Insulin Glargine
CONCLUSIONS: DAPA+SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA+SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.PMID:38412282 | DOI:10.1210/clinem/dgae105
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Donald C Simonson Marcia A Testa Ella Ekholm Maxwell Su Tina Vilsb øll Serge A Jabbour Marcus Lind Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Insulin | Lantus | Men | Metformin | Study